CADL

Candel Therapeutics Inc

13.40

Aug 26 • 11:04 AM ET -0.20 (-1.43%)

Healthcare Biotechnology USA Small NASD

Peers: CGON IDYA RCUS TNGX CRNX RYTM BMRN INCY KYMR KRYS

| Held by: XBI IWM VTI IWO VXF IBB KOMP VTWO IWC ITOT

Index	RUT
Market Cap	1.03B
Enterprise Value	873.69M
Income	-88.53M
Sales	0.00M
Book/sh	1.66
Cash/sh	2.63
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	55
IPO	Jul 27, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	8.09
P/C	5.09
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.09
Current Ratio	16.09
Debt/Eq	0.39
LT Debt/Eq	0.39
Option/Short	Yes / Yes

EPS (ttm)	-1.41
EPS next Y	-1.03
EPS next Q	-0.33
EPS this Y	-80.86%
EPS next Y	21.03%
EPS next 5Y	-
EPS past 3/5Y	-3.41% -3.52%
Sales past 3/5Y	- -
EPS Y/Y TTM	-108.75%
Sales Y/Y TTM	-
EPS Q/Q	-463.69%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-118.58% -

Insider Own	20.92%
Insider Trans	3.31%
Inst Own	62.03%
Inst Trans	11.69%
ROA	-56.37%
ROE	-81.84%
ROIC	-50.54%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	16.31%
SMA50	29.35%
SMA200	88.72%
Trades

Shs Outstand	76.12M
Shs Float	60.51M
Short Float	20.60%
Short Ratio	7.62
Short Interest	12.46M
52W High	13.95 -3.91%
52W Low	4.35 208.16%
Volatility	8.08% 6.30%
ATR (14)	0.75
RSI (14)	67.49
Beta	-0.46
Rel Volume	1.08
Avg Volume	1.64M
Volume	492,715

Perf Week	-0.70%
Perf Month	38.48%
Perf Quarter	66.52%
Perf Half Y	158.78%
Perf YTD	137.26%
Perf Year	124.92%
Perf 3Y	935.14%
Perf 5Y	70.98%
Perf 10Y	-
Recom	1.22
Target Price	21.00
Prev Close	13.60
Price	13.40
Change %	-1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-26	Initiated	Stifel	Buy	$22
Apr-20-26	Initiated	Cantor Fitzgerald	Overweight
Oct-28-25	Initiated	Stephens	Overweight	$15
Sep-03-25	Downgrade	BofA Securities	Buy → Neutral	$7
Jun-30-25	Resumed	H.C. Wainwright	Buy	$23
Feb-20-25	Initiated	Citigroup	Buy	$25
Feb-19-25	Initiated	Canaccord Genuity	Buy	$20
Feb-07-25	Initiated	BofA Securities	Buy	$15
Dec-02-22	Initiated	H.C. Wainwright	Buy	$11
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$18
Aug-23-21	Initiated	UBS	Buy	$9
Aug-23-21	Initiated	Jefferies	Buy	$22
Aug-23-21	Initiated	Credit Suisse	Outperform	$15

Show Previous Ratings

Today 08:05AM	Candel Therapeutics to Present at September Investor Conferences (GlobeNewswire)
Aug-13-26 03:27PM	CADL Rises As Biotech Eyes First Commercial Product in 2027 CEO Points To Meaningful Execution Toward BLA Submission In Q4 (Stocktwits) +10.49%
08:05AM	Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-26 03:08PM	CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug Eyes $10$16B Opportunity (Stocktwits)
Aug-03-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:05AM	Loading…
08:05AM	Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 (GlobeNewswire)
Jul-29-26 08:05AM	Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston (GlobeNewswire)
Jul-08-26 04:05PM	Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-26 12:27PM	CADL Stock Heads For Biggest Monthly Gains Since December 2024 Retail Says Our SLS Days Are Coming (Stocktwits)
08:05AM	Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors (GlobeNewswire)
Jun-25-26 03:53PM	Candel Therapeutics Designates Mark Sims as CCO (Exec Edge)
08:05AM	Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer (GlobeNewswire)
Jun-05-26 06:23AM	CADL Stock Heads For Best Week In A Month Heres Why Retail Is Bullish (Stocktwits) -8.20%
Jun-02-26 08:05AM	Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer (GlobeNewswire)
04:05PM	Loading…
Jun-01-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-26 04:05PM	Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting (GlobeNewswire) -9.92%
May-14-26 08:05AM	Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-26 08:05AM	Candel Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-04-26 08:05AM	Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting (GlobeNewswire) +16.38%
May-01-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-26 08:36AM	Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch (Proactive)
08:05AM	Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer (GlobeNewswire)
07:51AM	Nasdaq falls back after mixed earnings, Fed holds but signals dissent (Proactive)
Apr-02-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-17-26 02:53PM	Nasdaq rises with IBM, Goldman Sachs leading, as Iran strikes continue (Proactive)
10:35AM	Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 (Proactive)
08:05AM	Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors (GlobeNewswire)
Mar-12-26 09:33AM	Candel Therapeutics strengthens balance sheet as lead cancer therapy advances (Proactive)
08:05AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:05AM	Loading…
Mar-09-26 08:05AM	Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting (GlobeNewswire)
Mar-02-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-24-26 08:05AM	Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston (GlobeNewswire)
Feb-20-26 08:40AM	Candel Therapeutics prices $100M public offering (Proactive) -14.20%
05:55AM	Why Is Candel Therapeutics Stock Falling Friday? (Benzinga)
04:57AM	Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers-Grail, Candel Therapeutics, Copart In Focus (Benzinga)
Feb-19-26 09:40PM	Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire)
04:36PM	Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering (Proactive)
04:05PM	Candel Therapeutics Announces Proposed $100 Million Public Offering (GlobeNewswire)
04:01PM	Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer (GlobeNewswire)
Feb-11-26 08:05AM	Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit (GlobeNewswire)
Feb-02-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-20-26 09:12AM	New Strong Sell Stocks for January 20th (Zacks) -7.50%
Nov-17-25 04:05PM	Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 (GlobeNewswire)
Nov-13-25 08:25AM	Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.30%
Nov-04-25 09:00AM	Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors (GlobeNewswire)
Nov-03-25 08:05AM	Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-16-25 08:05AM	Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board (GlobeNewswire) -9.29%
Oct-15-25 08:31AM	Candel Therapeutics announces interim data from phase 1b CAN-3110 trial (TipRanks)
Oct-14-25 08:10AM	Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer (PR Newswire) -10.74%
08:10AM	Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. (GlobeNewswire)
08:05AM	Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine (GlobeNewswire)
Oct-03-25 09:05AM	Candel Therapeutics to Present at the SITC 2025 Annual Meeting (GlobeNewswire)
Sep-29-25 08:05AM	Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
Sep-17-25 08:05AM	Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
Sep-02-25 08:05AM	Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board (GlobeNewswire)
Aug-28-25 08:05AM	Candel Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-14-25 08:05AM	Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.63%
Jul-30-25 08:05AM	Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-25-25 08:23AM	Candel Therapeutics' CAN-2409 gains EMA orphan designation (Pharmaceutical Business Review)
Jul-24-25 08:05AM	Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jul-09-25 08:05AM	Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution (GlobeNewswire) +16.22%
Jun-25-25 12:00PM	Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jun-24-25 09:05AM	Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock (GlobeNewswire)
Jun-23-25 08:05AM	Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer (GlobeNewswire)
Jun-06-25 08:05AM	Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire) +8.83%
Jun-02-25 09:55AM	Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? (Zacks)
May-29-25 11:41PM	Candel Therapeutics, Inc. (CADL)'s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer (Insider Monkey) -6.84%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
May-28-25 08:05AM	Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer (GlobeNewswire) +6.07%
May-27-25 08:05AM	Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation (GlobeNewswire)
May-23-25 01:46AM	Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 (Insider Monkey)
May-22-25 05:05PM	Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire)
May-19-25 10:00AM	Best Momentum Stocks to Buy for May 19th (Zacks) +6.54%
07:49AM	New Strong Buy Stocks for May 19th (Zacks)
May-16-25 09:55AM	Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know (Zacks)
May-13-25 08:05AM	Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +7.68%
May-06-25 08:05AM	Candel Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -7.83%
Apr-23-25 04:05PM	Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire) +5.04%
Apr-01-25 08:01AM	Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients (GlobeNewswire)
Mar-27-25 03:46PM	Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients (Benzinga) -7.33%
Mar-26-25 04:05PM	Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment (GlobeNewswire) -8.76%
Mar-25-25 09:55AM	Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now (Zacks) -5.08%
Mar-20-25 08:00AM	Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 (GlobeNewswire) -7.30%
Mar-18-25 08:00AM	Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board (GlobeNewswire)
Mar-13-25 04:15PM	Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.20%
Feb-25-25 01:58PM	Candel Therapeutics stock drops despite OS improvement in PDAC trial (Clinical Trials Arena) -23.49%
08:00AM	Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Jan-13-25 08:00AM	Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 (GlobeNewswire) -5.01%
Jan-09-25 01:44AM	After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win (Pharma Voice)
Dec-19-24 01:44PM	Hedge Fund and Insider Trading News: Simon Sadler, Stanley Druckenmiller, Warren Buffett, Caxton Associates, Millennium Management, Saba Capital, Candel Therapeutics Inc (CADL), NVIDIA Corp (NVDA), and More (Insider Monkey) +52.53%
Dec-16-24 04:01PM	Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.81% +7.23%
Dec-12-24 11:00PM	Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire) +26.45% -31.12%
04:51PM	Candel Therapeutics Announces $80 Million Proposed Public Offering (GlobeNewswire)
Dec-11-24 04:09PM	Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily) +68.11%
01:07PM	Candel Therapeutics Prostate Cancer Therapy Shows Promise (Exec Edge)
11:54AM	Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily)
10:32AM	Candel Therapeutics stock up 172% after Phase III prostate cancer success (Clinical Trials Arena)
09:19AM	Candel Therapeutics Stock Surges Over 100% - Here's Why (Benzinga)
07:00AM	Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival (GlobeNewswire)

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

M.D.Dr. Paul-Peter Tak FOCIS

Senior VPMr. Charles Schoch

Ph.D.Dr. Francesca Barone M.D.

Chief Technical & Development OfficerDr. Seshu Tyagarajan Ph.D.

Chief People OfficerMs. Ileen B. Winick

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tyagarajan Seshu	Chief Technology Officer	Aug 17 '26	Sale	12.00	7,000	84,000	76,865	Aug 19 04:30 PM
SESHU TYAGARAJAN	Officer	Aug 17 '26	Proposed Sale	11.72	7,000	82,040		Aug 17 04:37 PM
Barone Francesca	Chief Scientific Officer	Jun 29 '26	Sale	10.06	23,447	235,769	77,362	Jul 01 04:22 PM
Tyagarajan Seshu	Chief Technology Officer	Jun 29 '26	Sale	10.02	7,000	70,151	83,865	Jul 01 04:22 PM
SESHU P TYAGARAJAN	Officer	Jun 29 '26	Proposed Sale	9.79	7,000	68,530		Jun 29 04:44 PM
FRANCESCA BARONE	Officer	Jun 29 '26	Proposed Sale	9.79	23,447	229,546		Jun 29 04:41 PM
Manning Paul B	Director	Feb 23 '26	Buy	5.45	550,458	2,999,996	2,763,527	Feb 26 07:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CADL

Candel Therapeutics Inc

Upgrade your Finviz experience